To include your compound in the COVID-19 Resource Center, submit it here.

Xoma, DNA long-term Xanelim data

XOMA and partner Genentech (DNA) said preliminary data from an open-label study of Raptiva efalizumab

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE